Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA backs second COVID-19 vaccine booster for some Americans

By Brian Buntz | March 29, 2022

COVID-19 vaccine

Image courtesy of Pixabay.

FDA has authorized a second booster dose of COVID-19 vaccine for individuals who are immunocompromised or 50 and over.

The expanded emergency use authorization applies to the vaccines from Pfizer (NYSE: Pfizer) and Moderna (Nasdaq: MRNA).

Individuals interested in obtaining a second booster dose must wait at least four months after receiving the first booster dose.

Immunocompromised individuals should have an equivalent level of immunocompromise to solid organ transplant recipients.

Immunocompromised patients at least 12 can receive the Pfizer vaccine. Conversely, the Moderna vaccine is available to those 18 and up.

To make the decision, the FDA reviewed real-world data from Israel, which indicated that an additional dose provides added protection against SARS-CoV-2 without causing unexpected side effects.

The Israeli data are from an ongoing, open-label, non-randomized trial involving healthcare workers. Participants in the study who had received three total doses of the Pfizer-BioNTech COVID-19 vaccine received a second booster of either Pfizer-BioNTech or Moderna COVID-19 vaccine at least four months after the first booster shot.

The agency had previously authorized a single booster for some immunocompromised individuals who had received a three-dose primary vaccination series.

“Current evidence suggests some waning of protection over time against serious outcomes from COVID-19 in older and immunocompromised individuals,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, in a statement.

FDA concluded that individuals facing a higher risk for severe disease, hospitalization and death from COVID-19 should be able to receive a second booster.

Pfizer shares ticked down 0.71% to $52.90 in early afternoon trading while Moderna shares were up 3.65%, hitting $179.41.

 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

institut pasteur dakar IPD African Union vaccine investment
African Union vaccine initiative receives $45M
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
This image shows the Moderna logo.
Moderna resizes its manufacturing footprint for a post-pandemic era
This is the logo of Pfizer.
Pfizer to close Durham and Morrisville, North Carolina facilities amid major restructuring effort
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE